Wilex AG (Wilex) is a oncology focused biopharmaceutical company. It discovers, develops and commercializes diagnostic and therapeutic products in the field of oncology. The therapeutic products developed by the company are based on monoclonal antibodies and small molecules. The diagnostic tests offered by the company are sold through Wilex, Inc., a subsidiary of the company, which is indulged in marketing of ontological biomarker tests, under the brand name Oncogene Science. Its product pipeline comprises Mesupron, is being studied for the treatment of breast cancer; WX-554, for the treatment of solid tumors and WX-037 for the treatment against tumor cell amongst others.
Wilex AGKey Recent Developments
Dec 04, 2012: Wilex AG Announces Restructuring, Reduces Workforce By 25% Aug 07, 2012: Wilex Appoints Jan Schmidt-Brand As CFO Jul 12, 2012: Wilex Reports Revenue Of €7.2m In H1 2012 Apr 12, 2012: Wilex Reports Revenue Of €3.7m In Q1 2012 Feb 27, 2012: Wilex Reports Revenue Of €9.9m In 2011
This comprehensive SWOT profile of Wilex AG provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table Of Contents
Wilex AG - Financial and Strategic SWOT Analysis Review Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Section 1 - About the Company 5 Wilex AG - Key Facts 5 Wilex AG - Key Employees 6 Wilex AG - Key Employee Biographies 7 Wilex AG - Major Products and Services 8 Wilex AG - Pharmaceutical Pipeline Products Data 9 Wilex AG, Pipeline Products by Therapy Area 9 Wilex AG, Pipeline Products by Development Phase 10 Wilex AG - History 12 Wilex AG - Company Statement 14 Wilex AG - Locations And Subsidiaries 15 Head Office 15 Other Locations and Subsidiaries 15 Section 2 - Company Analysis 16 Wilex AG - Business Description 16 Wilex AG - Corporate Strategy 18 Wilex AG - SWOT Analysis 19 SWOT Analysis - Overview 19 Wilex AG - Strengths 19 Strength - Sturdy RandD Activities 19 Strength - Broad Patent Portfolio 19 Wilex AG - Weaknesses 19 Weakness - Limited Operating Capability 19 Weakness - Business Shortcomings 20 Wilex AG - Opportunities 20 Opportunity - Strategic Initiatives 20 Opportunity - Strong Product Pipeline 20 Opportunity - Market Potential: Cancer 20 Wilex AG - Threats 21 Threat - Uncertain RandD Outcomes 21 Threat - Stringent Government Regulations 21 Threat - Competition Pressures 21 Wilex AG - Key Competitors 22 Section 3 - Company Financial Ratios 23 Financial Ratios - Capital Market Ratios 23 Financial Ratios - Annual Ratios 23 Performance Chart 25 Financial Performance 25 Financial Ratios - Interim Ratios 26 Financial Ratios - Ratio Charts 27 Section 4 - Company's Lifesciences Financial Deals and Alliances 28 Wilex AG, Pharmaceuticals and Healthcare, Deals By Year, 2007 to YTD 2013 28 Wilex AG, Pharmaceuticals and Healthcare, Deals By Type, 2007 to YTD 2013 29 Wilex AG, Recent Deals Summary 30 Section 5 - Company's Recent Developments 31 Wilex AG, Recent Developments 31 Dec 04, 2012: Wilex AG Announces Restructuring, Reduces Workforce By 25% 31 Aug 07, 2012: Wilex Appoints Jan Schmidt-Brand As CFO 31 Jul 12, 2012: Wilex Reports Revenue Of â¬7.2m In H1 2012 31 Apr 12, 2012: Wilex Reports Revenue Of â¬3.7m In Q1 2012 33 Feb 27, 2012: Wilex Reports Revenue Of â¬9.9m In 2011 34 Section 6 - Appendix 35 Methodology 35 Ratio Definitions 35 About GlobalData 39 Contact Us 39 Disclaimer 39
List of Tables
Wilex AG, Key Facts 5 Wilex AG, Key Employees 6 Wilex AG, Key Employee Biographies 7 Wilex AG, Major Products and Services 8 Wilex AG, Number of Pipeline Products by Therapy Area 9 Wilex AG, Number of Pipeline Products by Development Stage 10 Wilex AG, Pipeline Products By Therapy Area and Development Phase 11 Wilex AG, History 12 Wilex AG, Subsidiaries 15 Wilex AG, Key Competitors 22 Wilex AG, Ratios based on current share price 23 Wilex AG, Annual Ratios 23 Wilex AG, Interim Ratios 26 Wilex AG, Pharmaceuticals and Healthcare, Deals By Year, 2007 to YTD 2013 28 Wilex AG, Pharmaceuticals and Healthcare, Deals By Type, 2007 to YTD 2013 29 Wilex AG, Recent Deals Summary 30 Currency Codes 35 Capital Market Ratios 35 Equity Ratios 36 Profitability Ratios 36 Cost Ratios 37 Liquidity Ratios 37 Leverage Ratios 38 Efficiency Ratios 38
List of Figures
Wilex AG, Pipeline Products by Therapy Area 9 Wilex AG, Pipeline Products by Development Phase 10 Wilex AG, Performance Chart (2007 - 2011) 25 Wilex AG, Ratio Charts 27 Wilex AG, Pharmaceuticals and Healthcare, Deals By Year, 2007 to YTD 2013 28 Wilex AG, Pharmaceuticals and Healthcare, Deals by Type, 2007 to YTD 2013 29